Scientists at UCSF have created a drug carrier that physically anchors to cancer cell membranes, enhancing drug retention and effectiveness. This innovation addresses the challenge of maintaining therapeutic agents in tumor tissues long enough to be effective, potentially improving treatment outcomes with fewer side effects. Clinical trials for this technology are expected to begin later in 2026, marking a significant step forward in targeted cancer therapy development.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
2
Ali NematiWritten by Ali
